Avita Therapeutics Inc traded at 1.66 this Wednesday July 6th, increasing 0.08 or 5.06 percent since the previous trading session. Looking back, over the last four weeks, Avita Therapeutics Inc gained 9.93 percent. Over the last 12 months, its price fell by 69.26 percent. Looking ahead, we forecast Avita Therapeutics Inc to be priced at 1.40 by the end of this quarter and at 1.29 in one year, according to Trading Economics global macro models projections and analysts expectations.

Stock Price
Daily Change

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Peers Price Day Year
Accuray 2.01 -0.06 -2.90% -55.43%
Cochlear 202.65 -0.33 -0.16% -17.77%
CSL 285.75 -0.38 -0.13% 2.37%
Clinuvel Pharmaceuticals Ltd 16.28 0.04 0.25% -41.16%
Mayne Pharma 0.29 0.02 5.56% -14.93%
Nanosonics Ltd 3.96 -0.01 -0.13% -24.67%
Opthea Ltd 1.16 -0.02 -1.28% -13.16%
Paradigm Biopharmaceuticals Ltd 1.01 -0.05 -4.29% -50.74%
Pacific Edge 0.71 0 0% -40.83%
Polynovo Ltd 1.53 0.05 3.03% -35.71%
PYC Therapeutics Ltd 0.07 0.002 3.13% -57.42%
Ramsay Health Care 69.65 -1.19 -1.68% 8.19%
ResMed 32.10 -0.40 -1.23% -4.21%
Telix Pharmaceuticals Ltd 5.19 0.39 8.13% -9.11%

Indexes Price Day Year
AUALL 6799 14.60 0.22% -10.72%
AU200 6609 14.92 0.23% -9.97%

Avita Therapeutics Inc
AVITA Medical, Inc. is a regenerative medicine company. The Company is engaged in developing and commercializing a technology platform, which enables point-of-care autologous skin restoration for multiple unmet needs. It provides treatment solutions derived from the regenerative properties of a patient’s own skin. Its RECELL Autologous Cell Harvesting System (RECELL) enables clinicians to prepare Spray-On Skin Cells, an autologous skin cell suspension, which is sprayed onto the patient to regenerate natural healthy skin. The RECELL System is a single use disposable, stand-alone, battery operated, autologous cell harvesting device containing enzymatic and buffer solutions, sterile surgical instruments, and actuators to achieve the disaggregation and delivery of skin cells. The platform technology of the RECELL System allows for the preparation and delivery of Spray-On Skin Cells, an autologous cellular suspension comprised of the patient’s own skin cells.